At a glance
ClinicalIndex Comparison RecordN/AUnknown· 50 target
Drug / intervention
anti-PD-1 / PD-L1 monoclonal antibody and chemotherapy +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized, Prospective Study of the Efficacy and Safety of the 1st Treatment in Advanced Central NSCLC by PD-1/PD-L1 Inhibitor and Chemotherapy With/Without Bronchoscopic Microwave Intervention
Shanghai Pulmonary Hospital, Shanghai, China·interventional·Posted Apr 24, 2020·Updated Apr 24, 2020
In Brief
A clinical study evaluating bronchoscopic microwave intervention and anti-PD-1 / PD-L1 monoclonal antibody and chemotherapy for Effect Increased and Safety Issues. Targeting 50 participants.
Detailed Summary
A randomized, prospective study of the efficacy and safety of the first-line treatment in advanced central non-small cell lung cancer patients by anti-PD-1 / PD-L1 monoclonal antibody and chemotherapy versus anti-PD-1 / PD-L1 monoclonal antibody and chemotherapy combined with bronchoscopic microwave intervention
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsEffect Increased, Safety Issues
Countries--
Collaborators--
Timeline
N/AUnknownOverdue
202120222023202420252026
First PostedApr 2020
Enrollment StartMay 2020
Primary CompletionApr 2022
Study CompletionMay 2023
TodayJul 2026
First PostedApr 24, 2020
Enrollment StartMay 1, 2020
Primary CompletionApr 30, 2022
Study CompletionMay 1, 2023
TodayJul 1, 2026
Enrollment to primary: 2.0 yearsPosted 6.2 years ago
Interventions
bronchoscopic microwave interventionprocedure
bronchoscopic microwave intervention
anti-PD-1 / PD-L1 monoclonal antibody and chemotherapydrug
anti-PD-1 / PD-L1 monoclonal antibody and chemotherapy